Date: 2013-12-09
Type of information: Series A financing round
Company: Gecko Biomedical (France)
Investors: Omnes Capital (France) CM-CIC Capital Finance (France) CapDecisif Management (France)
Amount: €8 million
Funding type: series A financing round
Planned used: This investment will allow Gecko Biomedical to rapidly pursue its development plan, from industrialization through regulatory development, to obtain the CE mark for its adhesive liquid film for use in vascular reconstruction, as well as advancing its development in minimally invasive settings.
Others: * On December 9, 2013, Gecko Biomedical, a privately owned medical device company based in Paris that is developing novel biodegradable surgical wound closure solutions, has announced the closing of a €8 million ($11m) Series A financing round. The financing was co-led by Omnes Capital and CM-CIC Capital Finance, and joined by CapDecisif Management.
Created in 2013,Gecko Biomedical is dedicated to the development and the commercialization of biodegradable sealants and adhesives for wound closure in the field of surgery, with a key focus on minimally invasive surgery. Gecko Biomedical is developing products that are non-toxic, bind strongly to tissues and deliver ‘on-demand’ wound closure within the ‘wet’ and dynamic environments in the body. The Company’s technology and products are based on world-class research and intellectual property from the laboratories of Robert Langer (MIT) and Jeff Karp (Brigham & Women’s Hospital). Gecko Biomedical’s products include light-activated adhesive liquid films and patches, both of which improve the safety and efficiency of wound closure inside the body, and are ideally suited for use during minimally invasive surgery. The technologies have been successfully assessed in multiple surgical settings in preclinical models, thereby validating the benefits for a wide range of medical applications.
Gecko’s rapid development is based on the close relationships between the founders: Bernard Gilly and his iBionext Network; world-leading scientists Robert Langer from the Massachusetts Institute of Technology (Cambridge, MA, USA) and Jeff Karp from the Brigham and Women’s Hospital (Boston, MA, USA), both leading experts in the field of bioengineering and regenerative approaches; as well as with Christophe Bancel, member of the iBionext Network and founding CEO of Gecko Biomedical. Jacques Marescaux from the Institute of Research Against Digestive Cancer (Strasbourg, France), an expert in the use of laparoscopy (keyhole surgery), complements this team. Alexia Perouse of Omnes Capital and Karine Lignel of CM-CIC Capital Innovation will join the Gecko board of directors.
Therapeutic area: Medical devices
